Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

Cardona‐Benavides, Ignacio J.; Ramón, Cristina de; Gutiérrez, Norma C.

doi:10.3390/cells10020336

Cited by 68 publications

(60 citation statements)

References 206 publications

(257 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More than 90% of MM patients have cytogenetic abnormalities that are related to disease recurrence and prognosis (35)(36)(37)(38). We try to analyze the relationship between the bone marrow BCMA expression and some gene mutations including P53 deletion, IGH translocation, RB1 deletion, 1q21 amplification, and D13S319 deletion, but the results were not statistically significant (P>0.05).…”

Section: From the Perspective Of Prognostic Factorsmentioning

confidence: 99%

Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma

Shi

Xiao

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

The expression level of BCMA in bone marrow of 54 MM patients was detected in this study to explore the relationship between the BCMA expression and the classification, stage, and prognostic factors of MM. The BCMA expression level of the stable group and remission group was lower than that of the newly diagnosed group and relapse group (P=0.001). There was no significant difference in BCMA expression of MM patients in different types and stages (P>0.05), but it was found that for the newly diagnosed MM patients, the BCMA expression level of IgG patients was higher than that of IgA or light-chain patients (rank average 11.20 vs 5.44, P=0.014). There was no significant correlation between the BCMA expression and the age and serum creatinine of MM patients (P>0.05). And there was no significant difference in BCMA expression between patients with different levels of age and serum creatinine (P>0.05). But it was found that the BCMA expression level of the newly diagnosed MM patients was moderately positively correlated with their age (P=0.025, r=0.595). There was no significant correlation between the BCMA expression and serum β2-microglobulin, serum lactate dehydrogenase, free kap/lam ratio, and urine β2-microglobulin (P>0.05). But we found that the BCMA expression of patients with high serum β2-microglobulin was higher than that of patients with low serum β2-microglobulin (rank average 28.89 vs 17.54, P=0.017). And the BCMA expression of patients with abnormal serum free kap/lam ratio was higher than that of patients with normal ratio (rank average 28.49 vs 13.55, P=0.004). The BCMA expression was strongly positively correlated with 24-h urine protein, was moderately positively correlated with serum M protein and the percentage of plasma cells in bone marrow, was moderately negatively correlated with albumin and hemoglobin count, and was weakly positively correlated with serum corrected calcium (P<0.05). And it was found that the BCMA expression of positive serum immunofixation electrophoresis patients was higher than that of negative patients (rank average 29.94 vs 16.75, P=0.017). And we try to clarify the relationship between the bone marrow BCMA expression and the peripheral blood sBCMA expression. However, we have not found a clear correlation between them so far (P>0.05).

show abstract

Section: From the Perspective Of Prognostic Factorsmentioning

confidence: 99%

Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma

Shi

Xiao

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Section: Evolving Therapeutic Implicationsmentioning

confidence: 99%

“…However, these efforts have been severely challenged by the complex disease biology and molecular mechanisms of MM [99]. Detailed review on therapeutic implications in MM is beyond the scope of this article, but we will briefly describe some of the targeted agents that are currently explored [100]. BCL2 inhibitor Venetoclax as monotherapy and in combination with other anti-myeloma agents demonstrated improved outcome in early phases of clinical trials in patients with t (11;14) [101][102][103].…”

Section: Evolving Therapeutic Implicationsmentioning

confidence: 99%

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics

Awada

Thapa

Awada

et al. 2021

Cells

View full text Add to dashboard Cite

Multiple myeloma (MM) is a blood cancer characterized by the accumulation of malignant monoclonal plasma cells in the bone marrow. It develops through a series of premalignant plasma cell dyscrasia stages, most notable of which is the Monoclonal Gammopathy of Undetermined Significance (MGUS). Significant advances have been achieved in uncovering the genomic aberrancies underlying the pathogenesis of MGUS-MM. In this review, we discuss in-depth the genomic evolution of MM and focus on the prognostic implications of the accompanied molecular and cytogenetic aberrations. We also dive into the latest investigatory techniques used for the diagnoses and risk stratification of MM patients.

show abstract

“…In the era of molecular cytogenetic methodologies such as G-band karyotyping, fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), as well as more advanced novel genetic techniques, such as single nucleotide polymorphism (SNP) arrays and next-generation sequencing (NGS), it has become possible to better understand the molecular background of myelomagenesis [ 6 ]. Multiple myeloma is a genetically heterogeneous disease.…”

Section: Introductionmentioning

confidence: 99%

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications

Puła

Robak

Mikulski

et al. 2021

IJMS

View full text Add to dashboard Cite

Multiple myeloma (MM) is a genetically complex disease that results from a multistep transformation of normal to malignant plasma cells in the bone marrow. However, the molecular mechanisms responsible for the initiation and heterogeneous evolution of MM remain largely unknown. A fundamental step needed to understand the oncogenesis of MM and its response to therapy is the identification of driver mutations. The introduction of gene expression profiling (GEP) in MM is an important step in elucidating the molecular heterogeneity of MM and its clinical relevance. Since some mutations in myeloma occur in non-coding regions, studies based on the analysis of mRNA provide more comprehensive information on the oncogenic pathways and mechanisms relevant to MM biology. In this review, we discuss the role of gene expression profiling in understanding the biology of multiple myeloma together with the clinical manifestation of the disease, as well as its impact on treatment decisions and future directions.

show abstract

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

Cited by 68 publications

References 206 publications

Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma

Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications

Contact Info

Product

Resources

About